Profile
Dr. David Matthews is Head-Research at Reset Therapeutics, Inc.
Dr. Matthews was previously employed as VP-Drug Discovery & Exploratory Development by Pathway Therapeutics Ltd., VP-Drug Discovery & Exploratory Development by Pathway Therapeutics, Inc., Executive Director-Oncology Discovery by Exelixis, Inc., Group Leader by Metaxen Llc, and Scientist by Arris Pharmaceuticals Corp.
He received his doctorate degree from Imperial College London.
Former positions of David Matthews
| Companies | Position | End |
|---|---|---|
Pathway Therapeutics Ltd.
 Pathway Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Pathway Therapeutics Ltd. developed drugs for the treatment of cancer. The company was founded in 2007 and was headquartered in Auckland, New Zealand. | Corporate Officer/Principal | 2012-12-31 |
Pathway Therapeutics, Inc.
 Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 2012-12-31 |
Synchronicity Pharma, Inc.
 Synchronicity Pharma, Inc. Pharmaceuticals: OtherHealth Technology Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA. | Chief Tech/Sci/R&D Officer | - |
Metaxen LLC
 Metaxen LLC Pharmaceuticals: MajorHealth Technology Part of Exelixis, Inc., Metaxen LLC is an American company that provides compound screening assays and compound optimization services. The company was founded by Lutz B. Giebel, Michael Jay Ross. | Corporate Officer/Principal | - |
| Arris Pharmaceuticals Corp. | Corporate Officer/Principal | - |
Training of David Matthews
| Imperial College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Pathway Therapeutics, Inc.
Pathway Therapeutics, Inc. BiotechnologyHealth Technology Pathway Therapeutics, Inc. operates as a clinical stage, privately held, pharmaceutical company developing differentiated and best in class isoform specific PI3-kinase (PI3K) inhibitors for oncology, inflammatory and respiratory diseases. Its lead product include PWT33597, demonstrates excellent in vitro selectivity for its targets, with negligible activity against other protein kinases and other pharmacologically relevant targets at biologically active concentrations. The firm’s other product include PWT143, which has shown outstanding efficacy in in vivo models and has an excellent DMPK and safety profile suitable for advancement in multiple indications. The company was founded in 2010 by William A. Denny and Peter Robin Shepherd and is headquartered in San Francisco, CA. | Health Technology |
Metaxen LLC
Metaxen LLC Pharmaceuticals: MajorHealth Technology Part of Exelixis, Inc., Metaxen LLC is an American company that provides compound screening assays and compound optimization services. The company was founded by Lutz B. Giebel, Michael Jay Ross. | Health Technology |
| Arris Pharmaceuticals Corp. | |
Pathway Therapeutics Ltd.
Pathway Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Pathway Therapeutics Ltd. developed drugs for the treatment of cancer. The company was founded in 2007 and was headquartered in Auckland, New Zealand. | Health Technology |
Synchronicity Pharma, Inc.
Synchronicity Pharma, Inc. Pharmaceuticals: OtherHealth Technology Synchronicity Pharma, Inc. discovers, develops and commercializes novel therapeutics. Its products identify components of the circadian system that can be targeted to treat metabolic and related disorders, such as diabetes, obesity, and cardiovascular diseases. The company was founded by Ross S. Bersot, Joseph S. Takahashi, Masashi Yanagisawas and Ron Evans in 2008 and is headquartered in San Jose, CA. | Health Technology |
- Stock Market
- Insiders
- David Matthews
